CYNATA THERAPEUTICS LIMITED - Announcements

Market Cap $42.21M Add to my watchlist

Healthcare Biotechnology

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and... Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.More

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) is stepping up its trial activities in Australia’s nearest Asian neighbour, Indonesia. Recce’s flagship anti-infective, R327, can be applied as a gel – and this gel-based version of the drug has been of specific interest...

Announcements

Filter Results

All Price Sensitive Only

CYP	Appendix 4E & Annual Report	PRICE SENSITIVE	24/08/22	6.67MB	Share
CYP	Pipeline Update Following Strategic Portfolio Review	PRICE SENSITIVE	12/08/22	309.54KB	Share
CYP	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	27/07/22	479.1KB	Share
CYP	Notice of Allowance for Cynata US Patent	PRICE SENSITIVE	14/07/22	251.63KB	Share
CYP	Further data supports potency of Cynata MSCs	PRICE SENSITIVE	14/06/22	277.96KB	Share
CYP	Cynata Adds New Site for MEND Clinical Trial		30/05/22	246.31KB	Share
CYP	FDA Clears Cynata IND for Phase 2 Trial in GvHD	PRICE SENSITIVE	26/05/22	308.4KB	Share
CYP	Notification of cessation of securities - CYP		16/05/22	21.61KB	Share
CYP	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	29/04/22	457.17KB	Share
CYP	Cynata Advances Clinical Trial in Diabetic Foot Ulcers		21/04/22	247.03KB	Share
CYP	Updated Investor Presentation		08/03/22	1.32MB	Share
CYP	Notice of Allowance for Cynata Chinese Patent	PRICE SENSITIVE	28/02/22	248.65KB	Share
CYP	Appendix 4D & Half-Year Financial Statements	PRICE SENSITIVE	25/02/22	1.1MB	Share
CYP	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	28/01/22	489.79KB	Share
CYP	Cynata Receives Decision to Grant a Patent in Japan	PRICE SENSITIVE	27/01/22	248.67KB	Share
CYP	Cynata Receives $832,677 R&D Tax Incentive Refund		19/01/22	221.75KB	Share
CYP	FUJIFILM Cellular Dynamics Executes Manufacturing Agreement	PRICE SENSITIVE	29/12/21	253.58KB	Share
CYP	Cynata Commences DFU Clinical Trial	PRICE SENSITIVE	22/12/21	258.16KB	Share
CYP	Change of Registry Address		20/12/21	152.9KB	Share
CYP	Appendix 3Y- Dr Stewart Washer		02/12/21	192.41KB	Share
CYP	Appendix 3Y - Dr Geoffrey Brooke		01/12/21	191.3KB	Share
CYP	Site Initiation Visit Completed for CYP DFU Clinical Trial	PRICE SENSITIVE	18/11/21	261.46KB	Share
CYP	Results of Annual General Meeting		16/11/21	247.95KB	Share
CYP	AGM Presentations		16/11/21	1.97MB	Share
CYP	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	28/10/21	496.46KB	Share
CYP	Cynata Receives US$5m Fujifilm Fee	PRICE SENSITIVE	18/10/21	219.76KB	Share
CYP	Annual Report to shareholders		14/10/21	11.61MB	Share
CYP	Letter to Shareholders & Notice of Annual General Meeting		14/10/21	1.07MB	Share
CYP	Notification regarding unquoted securities - CYP		12/10/21	27.91KB	Share
CYP	DSMB Recommends Continuation of Cynata's MEND Trial	PRICE SENSITIVE	08/10/21	259.53KB	Share
CYP	Cynata Enters into a New Strategic Partnership with Fujifilm	PRICE SENSITIVE	30/09/21	276.88KB	Share
CYP	CYP Preclinical Heart Attack Study Published in Cytotherapy		28/09/21	262.51KB	Share
CYP	Date of AGM and Closing Date for Director Nominations		21/09/21	219.02KB	Share
CYP	Further Patents for Cynata Unique Cymerus Technology	PRICE SENSITIVE	15/09/21	251.78KB	Share
CYP	Further Canadian Patent for Cynata	PRICE SENSITIVE	31/08/21	250.76KB	Share
CYP	Appendix 4G		30/08/21	285.87KB	Share
CYP	Appendix 4E & Annual Report	PRICE SENSITIVE	30/08/21	11.79MB	Share
CYP	Cynata Receives Notice of Allowance from US Patent Office	PRICE SENSITIVE	26/08/21	194.84KB	Share
CYP	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	28/07/21	363.27KB	Share
CYP	Cynata Appoints Dr Jolanta Airey Chief Medical Officer		26/07/21	202.54KB	Share
CYP	Change of Registered Office		05/07/21	160.36KB	Share
CYP	Ethics Approval for Cynata's Clinical Trial in DFU	PRICE SENSITIVE	30/06/21	622.16KB	Share
CYP	Progress Toward Clinical Trial in Diabetic Foot Ulcers	PRICE SENSITIVE	28/06/21	165.1KB	Share
CYP	Cynata to Present at MST Access Investor Conference 15 June		11/06/21	181.59KB	Share
CYP	Cynata signs Licence Agreement with TekCyte	PRICE SENSITIVE	03/06/21	202.54KB	Share
CYP	Release of Securities from Voluntary Escrow		28/05/21	161.01KB	Share
CYP	First Patient Enrolled in Cynata MEND Clinical Trial	PRICE SENSITIVE	24/05/21	207.31KB	Share
CYP	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	28/04/21	331.3KB	Share
CYP	Cynata Expands trial in COVID-19 & Respiratory Failure	PRICE SENSITIVE	29/03/21	1.75MB	Share
CYP	Cynata Investor Presentation		12/03/21	1.34MB	Share
CYP	New Study to Investigate the High Potency of Cymerus MSCs		02/03/21	192.34KB	Share
CYP	Cynata Advances Planned Clinical Trial in DFU with TekCyte		01/03/21	199.39KB	Share
CYP	Appendix 4D & Half-Year Financial Statements	PRICE SENSITIVE	25/02/21	767.33KB	Share
CYP	Cynata Receives $1.39m R&D Tax Incentive Refund	PRICE SENSITIVE	22/02/21	162.94KB	Share
CYP	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	29/01/21	300.45KB	Share
CYP	Cleansing Notice		20/01/21	187.87KB	Share
CYP	Appendix 2A		20/01/21	166.86KB	Share
CYP	Completion of Entitlement Offer and Shortfall Placement	PRICE SENSITIVE	18/01/21	204.04KB	Share
CYP	Entitlement Offer Closing Date Reminder		11/01/21	165.34KB	Share
CYP	Cleansing Notice		31/12/20	187.19KB	Share
CYP	Appendix 2A		30/12/20	160.89KB	Share
CYP	2020 Review and Outlook		30/12/20	208.95KB	Share
CYP	Becoming a substantial holder		29/12/20	665.22KB	Share
CYP	Cleansing Notice		24/12/20	187.31KB	Share
CYP	Appendix 2A		23/12/20	167.17KB	Share
CYP	Letter to Ineligible Shareholders		21/12/20	266.97KB	Share
CYP	Offer Booklet and Entitlement & Acceptance Form	PRICE SENSITIVE	21/12/20	11.91MB	Share
CYP	Cynata Entitlement Offer Opens		21/12/20	201KB	Share
CYP	Cleansing Notice		21/12/20	187.34KB	Share
CYP	Cynata provides update on Placement and Appendix 2A		18/12/20	397.77KB	Share
CYP	Letter to Optionholders		15/12/20	229.95KB	Share
CYP	Notice Under Section 708AA of the Corporations Act		11/12/20	248.63KB	Share
CYP	Investor Presentation	PRICE SENSITIVE	11/12/20	997.27KB	Share
CYP	Proposed issue of Securities - CYP		11/12/20	36.44KB	Share
CYP	CYP Closes $15m Institutional Placement to Expand Pipeline	PRICE SENSITIVE	11/12/20	230.55KB	Share
CYP	Trading Halt	PRICE SENSITIVE	09/12/20	200.58KB	Share
CYP	Appendix 3Ys x 5		30/11/20	174.75KB	Share
CYP	Appendix 3G		30/11/20	134.72KB	Share
CYP	Replacement Constitution		24/11/20	645.49KB	Share
CYP	Results of Annual General Meeting		24/11/20	187.47KB	Share
CYP	AGM Presentations		24/11/20	1.72MB	Share
CYP	Cynata Technology Featured on Front Cover of Nature Medicine		18/11/20	204.36KB	Share
CYP	Phase 3 Osteoarthritis Clinical Trial Commences	PRICE SENSITIVE	11/11/20	1.7MB	Share
CYP	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	30/10/20	260.25KB	Share
CYP	AusBiotech Conference Presentation		29/10/20	1.41MB	Share
CYP	Annual Report to Shareholders		23/10/20	14.86MB	Share
CYP	Letter to Shareholders, Notice of AGM & Proxy Form		23/10/20	1.02MB	Share
CYP	Date of AGM & Closing Date for Director Nominations		06/10/20	162.26KB	Share
CYP	Potential Utility of Cymerus MSCs in Heart Attack Model	PRICE SENSITIVE	24/09/20	205.21KB	Share
CYP	Cynata Clinical Trial Results Published in Nature Medicine		15/09/20	216.84KB	Share
CYP	Appendix 3G		14/09/20	277.77KB	Share
CYP	Cymerus MSCs Effective in Preclinical Lung Disease Study	PRICE SENSITIVE	07/09/20	208.88KB	Share
CYP	Appendix 4G		25/08/20	222.01KB	Share
CYP	Appendix 4E & Annual Report	PRICE SENSITIVE	25/08/20	1.98MB	Share
CYP	Patient Enrolment Opens in COVID-19 Clinical Trial	PRICE SENSITIVE	24/08/20	194.2KB	Share
CYP	Appendix 3G		19/08/20	273.62KB	Share
CYP	Cynata Appoints Dr Geoff Brooke as Chairman	PRICE SENSITIVE	18/08/20	211.81KB	Share
CYP	Cynata Investor Presentation		14/08/20	1.89MB	Share
CYP	Notice of Allowance from Korean Patent Office		07/08/20	193.6KB	Share
CYP	Notification of Expiry of Unlisted Options		05/08/20	181.77KB	Share

CYP Appendix 4E & Annual Report
24/08/22	PRICE SENSITIVE	6.67MB	Share
CYP Pipeline Update Following Strategic Portfolio Review
12/08/22	PRICE SENSITIVE	309.54KB	Share
CYP Quarterly Activity Report & Appendix 4C
27/07/22	PRICE SENSITIVE	479.1KB	Share
CYP Notice of Allowance for Cynata US Patent
14/07/22	PRICE SENSITIVE	251.63KB	Share
CYP Further data supports potency of Cynata MSCs
14/06/22	PRICE SENSITIVE	277.96KB	Share
CYP Cynata Adds New Site for MEND Clinical Trial
30/05/22		246.31KB	Share
CYP FDA Clears Cynata IND for Phase 2 Trial in GvHD
26/05/22	PRICE SENSITIVE	308.4KB	Share
CYP Notification of cessation of securities - CYP
16/05/22		21.61KB	Share
CYP Quarterly Activity Report & Appendix 4C
29/04/22	PRICE SENSITIVE	457.17KB	Share
CYP Cynata Advances Clinical Trial in Diabetic Foot Ulcers
21/04/22		247.03KB	Share
CYP Updated Investor Presentation
08/03/22		1.32MB	Share
CYP Notice of Allowance for Cynata Chinese Patent
28/02/22	PRICE SENSITIVE	248.65KB	Share
CYP Appendix 4D & Half-Year Financial Statements
25/02/22	PRICE SENSITIVE	1.1MB	Share
CYP Quarterly Activity Report & Appendix 4C
28/01/22	PRICE SENSITIVE	489.79KB	Share
CYP Cynata Receives Decision to Grant a Patent in Japan
27/01/22	PRICE SENSITIVE	248.67KB	Share
CYP Cynata Receives $832,677 R&D Tax Incentive Refund
19/01/22		221.75KB	Share
CYP FUJIFILM Cellular Dynamics Executes Manufacturing Agreement
29/12/21	PRICE SENSITIVE	253.58KB	Share
CYP Cynata Commences DFU Clinical Trial
22/12/21	PRICE SENSITIVE	258.16KB	Share
CYP Change of Registry Address
20/12/21		152.9KB	Share
CYP Appendix 3Y- Dr Stewart Washer
02/12/21		192.41KB	Share
CYP Appendix 3Y - Dr Geoffrey Brooke
01/12/21		191.3KB	Share
CYP Site Initiation Visit Completed for CYP DFU Clinical Trial
18/11/21	PRICE SENSITIVE	261.46KB	Share
CYP Results of Annual General Meeting
16/11/21		247.95KB	Share
CYP AGM Presentations
16/11/21		1.97MB	Share
CYP Quarterly Activity Report & Appendix 4C
28/10/21	PRICE SENSITIVE	496.46KB	Share
CYP Cynata Receives US$5m Fujifilm Fee
18/10/21	PRICE SENSITIVE	219.76KB	Share
CYP Annual Report to shareholders
14/10/21		11.61MB	Share
CYP Letter to Shareholders & Notice of Annual General Meeting
14/10/21		1.07MB	Share
CYP Notification regarding unquoted securities - CYP
12/10/21		27.91KB	Share
CYP DSMB Recommends Continuation of Cynata's MEND Trial
08/10/21	PRICE SENSITIVE	259.53KB	Share
CYP Cynata Enters into a New Strategic Partnership with Fujifilm
30/09/21	PRICE SENSITIVE	276.88KB	Share
CYP CYP Preclinical Heart Attack Study Published in Cytotherapy
28/09/21		262.51KB	Share
CYP Date of AGM and Closing Date for Director Nominations
21/09/21		219.02KB	Share
CYP Further Patents for Cynata Unique Cymerus Technology
15/09/21	PRICE SENSITIVE	251.78KB	Share
CYP Further Canadian Patent for Cynata
31/08/21	PRICE SENSITIVE	250.76KB	Share
CYP Appendix 4G
30/08/21		285.87KB	Share
CYP Appendix 4E & Annual Report
30/08/21	PRICE SENSITIVE	11.79MB	Share
CYP Cynata Receives Notice of Allowance from US Patent Office
26/08/21	PRICE SENSITIVE	194.84KB	Share
CYP Quarterly Activity Report & Appendix 4C
28/07/21	PRICE SENSITIVE	363.27KB	Share
CYP Cynata Appoints Dr Jolanta Airey Chief Medical Officer
26/07/21		202.54KB	Share
CYP Change of Registered Office
05/07/21		160.36KB	Share
CYP Ethics Approval for Cynata's Clinical Trial in DFU
30/06/21	PRICE SENSITIVE	622.16KB	Share
CYP Progress Toward Clinical Trial in Diabetic Foot Ulcers
28/06/21	PRICE SENSITIVE	165.1KB	Share
CYP Cynata to Present at MST Access Investor Conference 15 June
11/06/21		181.59KB	Share
CYP Cynata signs Licence Agreement with TekCyte
03/06/21	PRICE SENSITIVE	202.54KB	Share
CYP Release of Securities from Voluntary Escrow
28/05/21		161.01KB	Share
CYP First Patient Enrolled in Cynata MEND Clinical Trial
24/05/21	PRICE SENSITIVE	207.31KB	Share
CYP Quarterly Activity Report & Appendix 4C
28/04/21	PRICE SENSITIVE	331.3KB	Share
CYP Cynata Expands trial in COVID-19 & Respiratory Failure
29/03/21	PRICE SENSITIVE	1.75MB	Share
CYP Cynata Investor Presentation
12/03/21		1.34MB	Share
CYP New Study to Investigate the High Potency of Cymerus MSCs
02/03/21		192.34KB	Share
CYP Cynata Advances Planned Clinical Trial in DFU with TekCyte
01/03/21		199.39KB	Share
CYP Appendix 4D & Half-Year Financial Statements
25/02/21	PRICE SENSITIVE	767.33KB	Share
CYP Cynata Receives $1.39m R&D Tax Incentive Refund
22/02/21	PRICE SENSITIVE	162.94KB	Share
CYP Quarterly Activity Report & Appendix 4C
29/01/21	PRICE SENSITIVE	300.45KB	Share
CYP Cleansing Notice
20/01/21		187.87KB	Share
CYP Appendix 2A
20/01/21		166.86KB	Share
CYP Completion of Entitlement Offer and Shortfall Placement
18/01/21	PRICE SENSITIVE	204.04KB	Share
CYP Entitlement Offer Closing Date Reminder
11/01/21		165.34KB	Share
CYP Cleansing Notice
31/12/20		187.19KB	Share
CYP Appendix 2A
30/12/20		160.89KB	Share
CYP 2020 Review and Outlook
30/12/20		208.95KB	Share
CYP Becoming a substantial holder
29/12/20		665.22KB	Share
CYP Cleansing Notice
24/12/20		187.31KB	Share
CYP Appendix 2A
23/12/20		167.17KB	Share
CYP Letter to Ineligible Shareholders
21/12/20		266.97KB	Share
CYP Offer Booklet and Entitlement & Acceptance Form
21/12/20	PRICE SENSITIVE	11.91MB	Share
CYP Cynata Entitlement Offer Opens
21/12/20		201KB	Share
CYP Cleansing Notice
21/12/20		187.34KB	Share
CYP Cynata provides update on Placement and Appendix 2A
18/12/20		397.77KB	Share
CYP Letter to Optionholders
15/12/20		229.95KB	Share
CYP Notice Under Section 708AA of the Corporations Act
11/12/20		248.63KB	Share
CYP Investor Presentation
11/12/20	PRICE SENSITIVE	997.27KB	Share
CYP Proposed issue of Securities - CYP
11/12/20		36.44KB	Share
CYP CYP Closes $15m Institutional Placement to Expand Pipeline
11/12/20	PRICE SENSITIVE	230.55KB	Share
CYP Trading Halt
09/12/20	PRICE SENSITIVE	200.58KB	Share
CYP Appendix 3Ys x 5
30/11/20		174.75KB	Share
CYP Appendix 3G
30/11/20		134.72KB	Share
CYP Replacement Constitution
24/11/20		645.49KB	Share
CYP Results of Annual General Meeting
24/11/20		187.47KB	Share
CYP AGM Presentations
24/11/20		1.72MB	Share
CYP Cynata Technology Featured on Front Cover of Nature Medicine
18/11/20		204.36KB	Share
CYP Phase 3 Osteoarthritis Clinical Trial Commences
11/11/20	PRICE SENSITIVE	1.7MB	Share
CYP Quarterly Activity Report & Appendix 4C
30/10/20	PRICE SENSITIVE	260.25KB	Share
CYP AusBiotech Conference Presentation
29/10/20		1.41MB	Share
CYP Annual Report to Shareholders
23/10/20		14.86MB	Share
CYP Letter to Shareholders, Notice of AGM & Proxy Form
23/10/20		1.02MB	Share
CYP Date of AGM & Closing Date for Director Nominations
06/10/20		162.26KB	Share
CYP Potential Utility of Cymerus MSCs in Heart Attack Model
24/09/20	PRICE SENSITIVE	205.21KB	Share
CYP Cynata Clinical Trial Results Published in Nature Medicine
15/09/20		216.84KB	Share
CYP Appendix 3G
14/09/20		277.77KB	Share
CYP Cymerus MSCs Effective in Preclinical Lung Disease Study
07/09/20	PRICE SENSITIVE	208.88KB	Share
CYP Appendix 4G
25/08/20		222.01KB	Share
CYP Appendix 4E & Annual Report
25/08/20	PRICE SENSITIVE	1.98MB	Share
CYP Patient Enrolment Opens in COVID-19 Clinical Trial
24/08/20	PRICE SENSITIVE	194.2KB	Share
CYP Appendix 3G
19/08/20		273.62KB	Share
CYP Cynata Appoints Dr Geoff Brooke as Chairman
18/08/20	PRICE SENSITIVE	211.81KB	Share
CYP Cynata Investor Presentation
14/08/20		1.89MB	Share
CYP Notice of Allowance from Korean Patent Office
07/08/20		193.6KB	Share
CYP Notification of Expiry of Unlisted Options
05/08/20		181.77KB	Share

REFRESH

First 2 3 4 5 6

(20min delay)
Last 23.5¢		Change 0.000(0.00%)		Mkt cap ! $42.21M

Open	High	Low	Value	Volume
22.0¢	23.5¢	22.0¢	$20.38K	90.67K

Buyers (Bids)

No.	Vol.	Price($)
1	86380	21.0¢

Sellers (Offers)

Price($)	Vol.	No.
23.5¢	12372	2

View Market Depth

No.	Vol.	Price($)
1	86380	0.210
4	165257	0.200
2	13135	0.195
1	30000	0.190
3	102017	0.185

Price($)	Vol.	No.
0.235	12372	2
0.240	91350	1
0.245	10000	1
0.250	42019	2
0.275	21895	1

Last trade - 16.10pm 09/05/2024 (20 minute delay)


Last 23.0¢		Change 0.000 ( 2.22 %)
Open	High	Low	Volume
23.0¢	23.0¢	23.0¢	10474
Last updated 11.40am 09/05/2024 ?

CYP (ASX) Chart

CYNATA THERAPEUTICS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories